131 related articles for article (PubMed ID: 2786308)
1. T lymphocyte activation in euthyroid Graves' ophthalmopathy: soluble interleukin 2 receptor release, cellular interleukin 2 receptor expression and interleukin 2 production.
Lai KN; Leung JC; Chow CC; Cockram CS
Acta Endocrinol (Copenh); 1989 May; 120(5):602-9. PubMed ID: 2786308
[TBL] [Abstract][Full Text] [Related]
2. T-lymphocyte activation in IgA nephropathy: serum-soluble interleukin 2 receptor level, interleukin 2 production, and interleukin 2 receptor expression by cultured lymphocytes.
Lai KN; Leung JC; Lai FM; Tam JS
J Clin Immunol; 1989 Nov; 9(6):485-92. PubMed ID: 2630571
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy.
Chow CC; Lai KN; Leung JC; Chan JC; Cockram CS
Clin Endocrinol (Oxf); 1990 Sep; 33(3):317-21. PubMed ID: 2253407
[TBL] [Abstract][Full Text] [Related]
4. Suppressed natural killer cell activity in patients with euthyroid Graves' ophthalmopathy.
Pedersen BK; Perrild H; Feldt-Rasmussen U; Christensen T; Klarlund K; Hansen JM
Autoimmunity; 1989; 2(4):291-8. PubMed ID: 2491612
[TBL] [Abstract][Full Text] [Related]
5. T lymphocyte activation in Graves' disease.
Marazuela M; Vargas JA; Durántez A; Alvarez-Mon M
Endocr Res; 1994 Aug; 20(3):291-306. PubMed ID: 7995258
[TBL] [Abstract][Full Text] [Related]
6. In vitro production of interferon-gamma by peripheral blood from patients with Graves' disease, Hashimoto's thyroiditis and rheumatoid arthritis.
Matsubayashi S; Akasu F; Kasuga Y; Snow K; Keystone E; Volpé R
Clin Exp Immunol; 1990 Oct; 82(1):63-8. PubMed ID: 1976464
[TBL] [Abstract][Full Text] [Related]
7. Methimazole therapy in Graves' disease influences the abnormal expression of CD69 (early activation antigen) on T cells.
Corrales JJ; López A; Ciudad J; Mories MT; Miralles JM; Orfao A
J Endocrinol; 1997 Dec; 155(3):491-500. PubMed ID: 9487994
[TBL] [Abstract][Full Text] [Related]
8. The effect of carbimazole therapy on interleukin 2, interleukin 2 receptors and free radicals.
Wilson R; McKillop JH; Buchanan LM; Bradley H; Smith WE; Thomson JA
Autoimmunity; 1990; 8(1):3-7. PubMed ID: 2129783
[TBL] [Abstract][Full Text] [Related]
9. Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin 2 receptor expression in activated T-lymphocytes in vitro.
Lai KN; Leung JC; Lai FM
Pathology; 1991 Jul; 23(3):224-8. PubMed ID: 1838146
[TBL] [Abstract][Full Text] [Related]
10. T lymphocyte activation in chronic hepatitis B infection: interleukin 2 release and its receptor expression.
Lai KN; Leung JC; Tam JS; Leung NW
Am J Gastroenterol; 1989 Dec; 84(12):1532-7. PubMed ID: 2596455
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy].
Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):93-101. PubMed ID: 15504312
[TBL] [Abstract][Full Text] [Related]
12. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
Wakelkamp IM; Prummel MF; Wiersinga WM
Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406
[TBL] [Abstract][Full Text] [Related]
13. [Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy].
Yang H; Wu Z; Huang X; Xie C; Yang P
Yan Ke Xue Bao; 1999 Jun; 15(2):78-80. PubMed ID: 12579704
[TBL] [Abstract][Full Text] [Related]
14. Distinctive response of thyroid-infiltrating mononuclear cells to B cell activation through CD40 and interleukin-4 in Graves' patients.
Itoh M; Uchimura K; Yamamoto K; Makino M; Imamura S; Kobayashi T; Fujiwara K; Kato T; Hayakawa N; Sawai Y; Nagasaka A; Iwase K; Nomura T; Hagino Y
Cytokine; 2002 Aug; 19(3):107-14. PubMed ID: 12242076
[TBL] [Abstract][Full Text] [Related]
15. Soluble interleukin-2 receptor in sera of patients with Graves' disease.
Balázs C; Farid NR
Acta Med Hung; 1991; 48(1-2):3-11. PubMed ID: 1813855
[TBL] [Abstract][Full Text] [Related]
16. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy.
De Bellis A; Sansone D; Coronella C; Conte M; Iorio S; Perrino S; Battaglia M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
Clin Endocrinol (Oxf); 2005 Jan; 62(1):24-9. PubMed ID: 15638866
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte subpopulations in Graves' ophthalmopathy.
Felberg NT; Sergott RC; Savino PJ; Blizzard JJ; Schatz NJ; Amsel J
Arch Ophthalmol; 1985 May; 103(5):656-9. PubMed ID: 3873236
[TBL] [Abstract][Full Text] [Related]
18. Suppressor T lymphocyte function in Graves' disease.
Hallengren B; Forsgren A
Acta Endocrinol (Copenh); 1982 Nov; 101(3):354-8. PubMed ID: 6216711
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood T lymphocyte sensitisation against calsequestrin and flavoprotein in patients with Graves' ophthalmopathy.
Nguyen B; Gopinath B; Tani J; Wescombe L; Wall JR
Autoimmunity; 2008 Aug; 41(5):372-6. PubMed ID: 18568642
[TBL] [Abstract][Full Text] [Related]
20. A study on the role of zinc on the immune response and body metabolism--a contribution of trace elements.
Tanaka Y
Kobe J Med Sci; 1989 Dec; 35(5-6):299-309. PubMed ID: 2635244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
